Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.
By T. Dellit, R. Owens, J. Mcgowan, D. Gerding, Robert A. Weinstein, J. Burke, W. Huskins, David L. Paterson, Neil O. Fishman, C. Carpenter and 3 more. Clinical Infectious Diseases, 2007
2,493 citations recorded by the source corpus.
Subfields: Applied Microbiology and Biotechnology, Clinical Biochemistry, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/0ff6dffc0193c213bfaca848ca5d71eef8c16d73
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Applied Microbiology and Biotechnology
In Clinical Biochemistry
In Infectious Diseases
Citations in the corpus
- Core Elements of Hospital Antibiotic Stewardship Programs From the Centers for Disease Control and Prevention (2014, positive): “Education has been found to be most effective when paired with corresponding interventions and measurement of outcomes [5].”
- Antimicrobial-associated risk factors for Clostridium difficile infection. (2008, methodology): “In particular, the BI/NAP1 strain has been isolated with varying frequency in at least 8 North American outbreaks since 2001, and isolates from these outbreaks have been fully resistant to all of the fluoroquinolones tested [12, 18].”
- The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. (2008, positive): “Indeed, the IDSA has recently released guidelines on appropriate antibiotic stewardship to try to minimize antibiotic misuse [82].”
- General Principles of Antimicrobial Therapy (2011, background): “components recommended for these programs include the following: prospective audit and feedback of antimicrobial prescriptions to clinicians, formulary restriction, education, use of clinical order sets and guidelines, de-escalation of therapy, and intravenous to oral antimicrobial conversion when a”
- 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. (2013, background): “Optimizing use of currently available antibacterial drugs, via improved resistance data collection, surveillance, prevention, and control measures, including antimicrobial stewardship efforts, remains vital to combating bacterial resistance [9, 59, 65, 66].”